Post-Market Clinical Follow-Up (PMCF) is the continuous, proactive collection and evaluation of clinical data on a CE-marked medical device once it is on the market. Required under EU MDR 2017/745 Annex XIV Part B, PMCF confirms safety and performance across the device’s lifetime and keeps the clinical evaluation current.
What is Post-Market Clinical Follow-Up (PMCF)?
PMCF sits in the post-market phase of the device lifecycle, after CE marking and market placement. It is the clinical arm of post-market surveillance (PMS), where PMS captures all field experience, including complaints and vigilance data, and PMCF proactively gathers new clinical evidence on how the device performs in real-world use within its intended purpose. The data feeds back into the Clinical Evaluation Report (CER) and the risk management file, so the manufacturer’s evidence base stays current rather than frozen at the point of certification.
Why Post-Market Clinical Follow-Up (PMCF) matters in medical device development
Under EU MDR 2017/745, PMCF is a legal obligation, not a nice-to-have. Article 61(11) requires the clinical evaluation to be updated throughout the device’s lifetime with data from the PMCF plan. Skipping or under-scoping PMCF is a common finding in Notified Body audits and can hold up certificate renewal.
The stakes are concrete. Missing PMCF data leaves safety signals undetected, which raises patient risk and exposes the manufacturer to field safety corrective actions. A weak plan can delay a CE certificate or trigger conditions that restrict how a device is sold. For a startup, that delay can mean missing a launch window; for an established OEM, it can mean a portfolio-wide remediation program. Strong PMCF produces the evidence that supports label expansions and smoother renewal.
How Post-Market Clinical Follow-Up (PMCF) works
PMCF runs as a documented cycle tied to the wider PMS system. Two documents anchor it: the PMCF plan and the PMCF evaluation report, whose structure follows MDCG 2020-7 and MDCG 2020-8, respectively.
A typical program covers these steps:
- Define objectives: state the clinical questions the plan answers, mapped to the gaps and residual risks identified in the CER and the risk management file (ISO 14971).
- Select methods: choose proportionate activities: PMCF surveys, device registries, structured literature review, real-world data analysis, or a formal PMCF clinical investigation under ISO 14155:2026 when higher-risk questions demand it.
- Set milestones: fix data collection intervals and analysis points across the device lifetime, longer for implantables and Class III devices.
- Analyze and report: compile findings in the PMCF evaluation report, then feed conclusions into the CER, the risk file, and the Periodic Safety Update Report (PSUR) under Article 86.
- Act on signals: update labeling, instructions for use, or the risk analysis when data shifts the benefit-risk picture.
The plan applies to every device class, though depth scales with risk. Even when a manufacturer concludes that no proactive study is needed, the plan must record that rationale.
Common challenges and best practices
The frequent mistake is treating PMCF as a paperwork exercise: a generic plan copied across a product family, with objectives that do not trace to real CER gaps. Notified Bodies flag this quickly. Another is collecting data that never loops back into the CER or risk file, so the effort produces no usable evidence.
What good looks like: objectives written as answerable clinical questions, methods sized to the device’s risk and novelty, and clear ownership shared between QA/RA, clinical, and engineering. Build the PMCF plan alongside the CER so the two stay aligned. Set realistic intervals and hold to them. For higher-risk devices, plan the follow-up horizon early, since Class III programs can run for many years. Keep the link to PMS and vigilance explicit, so that complaint and adverse-event trends inform PMCF and the reverse.
How SJML helps with Post-Market Clinical Follow-Up (PMCF)
Syrma Johari MedTech (SJML) supports PMCF as part of its Compliance-as-a-Service offering. The QARA team helps manufacturers plan and run post-market surveillance and PMCF, including PMCF plan development, clinical data management, and the PMCF evaluation report, alongside PSUR and PMSR preparation. Because SJML works across clinical evaluation (CEP and CER), risk management to ISO 14971, and ISO 13485 quality systems, PMCF activities connect to the wider technical documentation rather than sitting in isolation. Support scales from startups placing a first device on the EU market to established OEMs managing large portfolios.
Frequently asked questions
Yes. Under EU MDR 2017/745 Annex XIV Part B, every manufacturer placing a CE-marked device on the EU market must address PMCF in the PMS plan, with no exemption by class. If a manufacturer decides proactive PMCF activities are not warranted, the PMCF plan must still exist and document the justification for that decision.
Post-market surveillance (PMS) is the overarching system that collects all field experience, including complaints, vigilance reports, and literature monitoring. PMCF is the clinical component of PMS: the proactive, structured collection of new clinical data on device safety and performance in normal use. PMCF findings feed back into PMS outputs such as the PSUR and the clinical evaluation.
Two core documents: the PMCF plan and the PMCF evaluation report. The plan defines objectives, methods, and timing before data collection begins, and its structure commonly follows MDCG 2020-7. The evaluation report summarizes the findings and their impact, following MDCG 2020-8. Conclusions from the report update the Clinical Evaluation Report, the risk management file, and the PSUR.
PMCF and the Clinical Evaluation Report (CER) form a loop. The CER identifies clinical gaps and residual risks that the PMCF plan is designed to close. Data gathered through PMCF then flows back to update the CER throughout the device lifetime, as required by Article 61(11). If PMCF findings change the benefit-risk conclusion, the CER and labeling are revised.
Related terms
- Post-Market Surveillance (PMS)
- Clinical Evaluation Report (CER)
- Periodic Safety Update Report (PSUR)
- Vigilance Reporting
- EU MDR 2017/745
